POWER THE COURSE OF FIGHTING DISEASES AND SAVING LIVES

LAV is a global biomedical venture capital firm with offices in Shanghai, Palo Alto, and Hong Kong. Originated in 2008 as a corporate venture subsidiary of Eli Lilly, we spun off to become an independent investment management company in 2011. Our team of over 50 distinguished professionals, experienced in science, medicine, investment, and operations, embraces a culture of integrity, teamwork, diligence, and scientific rigor.

LAV has significant biomedical resources, and deep expertise in preclinical and clinical development, regulatory know-hows, and market insights. We offer a strong global perspective and connections, supported by the extensive consolidated experience of our team members overseas and our large network of scientific advisors. Our vision is to become the trusted partner for exceptional entrepreneurs seeking smart capital, and to help build great companies that develop breakthrough products to treat diseases and improve human health.

We bet on people. We are highly selective, but when we find entrepreneurs with a unique combination of ambition, experience, leadership, and integrity, we are thrilled to support them with the long-term capital they need to succeed. In working with such exceptional entrepreneurs, we adhere to the principle of “first, do no harm.” Where needed, we provide significant value by helping make strategic decisions, recruit executives, secure industry contacts, and explore business development opportunities.

We also bet on products. We constantly ask ourselves, “What will be the industry’s best-selling products 5-10 years from now?” and we seek out or build companies with such products. Our investment team stays up-to-date on global medical literature, clinical studies, and insights from key opinion leaders and industry experts.

At our core is a focus on quality science. LAV does not invest in low-quality products or engage in “quick flip” investments built on hype. We only invest when attractive financial returns align with our commitment to providing truly science-based, high-quality products that treat diseases and save lives.

Last but not the least, we are long-term thinkers. We are not driven by overnight success; instead, we focus on building sustainable companies for the decades ahead, catalyzing global medical innovations, and meeting humanity’s ever-increasing demand for better healthcare. This long-term thinking guides every investment decision, shapes our organizational development, and defines how we treat our partners.